MARKET WIREReuters • 1h ago
US voters in a sour economic mood heading into midterm elections - ReutersUS voters in a sour economic mood heading into midterm elections Reuters
Why NDRA Stock dropped -2.66% Today — RQD Quant Desk Flash
$4.75 -2.66% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.72
ENDRA Life Sciences Inc. (NDRA) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • SELL / AVOID
Cap $7.3M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on NDRA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $4.75 (-2.66% 1D, market cap $7.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NDRA ranks #489 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does NDRA compare to IRIX and ITOC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for NDRA?
▼
Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $0 in revenue, -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.72 (-0.67%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C-
Each axis scored 0–20
12M PRICE TARGET CONE-7.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NDRA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (42/100 Composite)
🔍 WHY NDRA SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+14/20 pts (33% of score)
FRED Regime × Technicals: 45% of 52W Range • RSI-14 at 45 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (24% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$5.14-7.6% Next Q
50
Q2 (-2Q)Grade D$4.75+1.5% Next Q
47
Q3 (-1Q)Grade D$4.82-1.5% Next Q
45
CurrentGrade D-$4.75-7% Hist 90D α
42
Trajectory: C- (50) → D- (42)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a NDRA Turnaround Squeeze
While NDRA currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($5.44) and Max Pain ($4.99) forces dealer call-delta covering toward $7.30.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $NDRA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “NDRA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why NDRA Stock dropped -2.66% Today — RQD Quant Desk Flash
ENDRA Life Sciences Inc. (NDRA) dropped -2.66% to $4.75, trading at 45% of its 52-week range ($2.96 – $6.95). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 45% of its 52-week range ($2.96 – $6.95) with RSI-14 at 45 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $4.75 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live NDRA Headlines & Catalysts
MARKET WIREReuters • 1h ago
China's foreign minister pushes for dialogue to resolve Middle East conflict - ReutersChina's foreign minister pushes for dialogue to resolve Middle East conflict Reuters
MARKET WIREReuters • 1h ago
COMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag - ReutersCOMMENTARY: Asia's crude oil imports back to pre-war levels but refined fuels lag Reuters
MARKET WIREReuters • 2h ago
Iranians have left Doha talks, draft proposal for US deal being circulated, official says - ReutersIranians have left Doha talks, draft proposal for US deal being circulated, official says Reuters
MARKET WIREReuters • 5h ago
Saudi civil defence sounds all-clear after alerts in southern cities - ReutersSaudi civil defence sounds all-clear after alerts in southern cities Reuters
MARKET WIREReuters • 6h ago
World's energy supply buffers have been eroded, ADNOC CEO says - ReutersWorld's energy supply buffers have been eroded, ADNOC CEO says Reuters
MARKET WIREReuters • 6h ago
Afghanistan asks US to act responsibly on deporting Afghan immigrants back home - ReutersAfghanistan asks US to act responsibly on deporting Afghan immigrants back home Reuters
MARKET WIREReuters • 6h ago
Anthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows - ReutersAnthropic plans to sell $3.5 billion of shares to Japan investors in IPO, filing shows Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NDRA)
- ✓Walkthrough of NDRA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
NDRA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -3.85%▲ ASCENDING TRIANGLE
2026-11-02O $4.74H $4.88L $4.74C $4.75VOL 14.6K
RES: $6.82SUP: $4.29SMA50: $5.44SMA200: $4.81
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
NDRA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on NDRA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for NDRA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for NDRA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NDRA)
Health Care Rank #489 of 1016
⚔️ IRIX vs NDRA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (NDRA vs. IRIX, ITOC, NUWE, NXL)
Industry: Biotechnology: Electromedical & Electrotherapeutic Apparatus (26 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, ENDRA Life Sciences Inc. (NDRA) ranks #489 by composite RQD confidence (42/100, grade D-) and #919 by equity capitalization ($7.3M). Within this direct 5-issuer industry benchmark cohort, NDRA leads on earnings valuation at N/A trailing P/E, while NDRA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. NDRA currently leads its immediate peer cohort in composite quantitative strength at 42/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| NDRA
ACTIVE
ENDRA Life Sciences Inc. | D- | 42/100 | — | — | -35.0% | -2.66% | $7.3M | Benchmark Subject |
| IRIX IRIDEX Corporation | E | 28/100 | — | 36.5% | -35.0% | -1.68% | $12.7M | /irix-vs-ndra → |
| ITOC iTonic Holdings Ltd (Class A) | E | 33/100 | — | 62.6% | -35.0% | -8.78% | $20.9M | /itoc-vs-ndra → |
| NUWE Nuwellis Inc. | D- | 35/100 | — | 62.0% | -35.0% | -1.73% | $2.3M | /nuwe-vs-ndra → |
| NXL Nexalin Technology Inc. | E | 32/100 | — | 79.7% | -35.0% | -1.84% | $1.9M | /nxl-vs-ndra → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001681682In its most recent audited fiscal period (FY2025, filed 2025-12-31), ENDRA Life Sciences Inc. (NDRA) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$7.0M, operating cash flow of -$5.2M, and free cash flow of -$5.2M (+29.9% YoY). On the balance sheet, NDRA closed FY2025 with $3.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$7.0M | -$5.2M | -$5.2M | $3.9M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$11.5M | -$7.4M | -$7.4M | $4.5M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$10.1M | -$9.5M | -$9.5M | — | — |
3. NDRA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs NDRA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, ENDRA Life Sciences Inc. (NASDAQ: NDRA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $4.75 (-2.66% 1D, market cap $7.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NDRA ranks #489 in composite RQD confidence.
How does NDRA compare to IRIX and ITOC in the Health Care sector?
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), NDRA carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IRIX (IRIDEX Corporation) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $12.7M) and ITOC (iTonic Holdings Ltd (Class A)) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $20.9M). Among the 5-stock peer group, NDRA leads on earnings multiple (N/A) while NDRA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for NDRA?
Per NDRA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001681682), ENDRA Life Sciences Inc. generated $0 in revenue, -$7.0M in net income, and -$5.2M in free cash flow against $3.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is NDRA trading relative to its 50-day, 200-day, and 52-week technical levels?
NDRA last traded at $4.75 (-2.66% on volume of 10,574 shares), positioning the stock -12.68% below its 50-day simple moving average ($5.44) and -1.25% below its 200-day simple moving average ($4.81). Across its 52-week range of $2.96 to $6.95, NDRA sits at the 44.9% percentile with a 14-day RSI of 45.0 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($4.16 to $5.34).
NDRA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is NDRA stock moving today?
Why NDRA Stock dropped -2.66% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.